BCAX

Bicara Therapeutics Inc

Add to Watchlist

Advanced Chart

11.750

-0.18(-1.509%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

12.010

Open

11.900

VWAP

11.88

Vol

204.55K

Mkt Cap

640.80M

Low

11.690

Amount

2.43M

EV/EBITDA(TTM)

Total Shares

54.54M

188.55M

EV/OCF(TTM)

P/S(TTM)

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

6 Analyst Rating

177.45% Upside

Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 32.60 USD with a low forecast of 8.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

177.45% Upside

Current: 11.750

Low

8.00

Averages

32.60

High

48.00

177.45% Upside

Current: 11.750

Low

8.00

Averages

32.60

High

48.00

Wells Fargo

Eva Fortea Verdejo

Underweight -> Equal Weight

upgrade

2025-05-23

Reason

Wells Fargo

Eva Fortea Verdejo

Price Target

2025-05-23

upgrade

Underweight -> Equal Weight

Reason

Wells Fargo analyst Eva Fortea Verdejo upgraded Bicara Therapeutics to Equal Weight from Underweight with an unchanged price target of $8.

Wells Fargo

Underweight -> Equal Weight

upgrade

2025-05-23

Reason

Wells Fargo

Price Target

2025-05-23

upgrade

Underweight -> Equal Weight

Reason

Wells Fargo upgraded Bicara Therapeutics to Equal Weight from Underweight with an unchanged price target of $8. The form says its Underweight thesis has largely played out on ficerafusp and petosemtamab's head and neck squamous cell carcinomas update. A lower probability of sucess for ficerafusp is largely priced in at current share levels, with a lack of catalysts for upside keeping Bicara range bound in the medium term, the analyst tells investors in a research note.

H.C. Wainwright

Buy

downgrade

$44 -> $41

2025-05-16

Reason

H.C. Wainwright

Price Target

$44 -> $41

2025-05-16

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Bicara Therapeutics to $41 from $44 and keeps a Buy rating on the shares following the Q1 report

Wells Fargo

Eva Fortea Verdejo

Sell

Initiates

2025-04-17

Reason

Wells Fargo

Eva Fortea Verdejo

Price Target

2025-04-17

Initiates

Sell

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$45 → $44

2025-04-07

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$45 → $44

2025-04-07

Maintains

Strong Buy

Reason

Cantor Fitzgerald

Eric Schmidt

Buy

Reiterates

$13

2025-03-13

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

$13

2025-03-13

Reiterates

Buy

Reason

Group Dinner Meeting to be held in San Francisco on March 12 hosted by Cantor Fitzgerald.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bicara Therapeutics Inc (BCAX.O) is -5.42, compared to its 5-year average forward P/E of -8.66. For a more detailed relative valuation and DCF analysis to assess Bicara Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.66

Current PE

-5.42

Overvalued PE

-4.72

Undervalued PE

-12.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.64

Current EV/EBITDA

-1.06

Overvalued EV/EBITDA

0.76

Undervalued EV/EBITDA

-8.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00